Acadia Pharmaceuticals
ACAD
213 hedge funds and large institutions have $3.09B invested in Acadia Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 94 increasing their positions, 62 reducing their positions, and 39 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 62
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less funds holding
Funds holding: 215 → 213 (-2)
3% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 39
11% less capital invested
Capital invested by funds: $3.47B → $3.09B (-$383M)
11% less call options, than puts
Call options by funds: $88.5M | Put options by funds: $99.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$81.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$52.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$41.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.2M |
| 5 |
O
OrbiMed
New York
|
+$30.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$32M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$29.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.3M |
| 4 |
BAMCO Inc
New York
|
-$22.7M |
| 5 |
VAM
Visium Asset Management
New York
|
-$17.8M |
ACAD Hedge Fund Activity: Q1 2016 in Review
213 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2016, worth a combined $3.09B — down 11% from $3.47B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ACAD and 38 opened new positions — a net loss of 1 holder — while 62 trimmed existing stakes and 94 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $81.4M. The largest seller was Westfield Capital Management, cutting an estimated $32M.
- 213 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2016, down from 215 in Q4 2015.
- Funds reported $3.09B of Acadia Pharmaceuticals stock for Q1 2016, down 11% quarter-over-quarter.
- 38 funds opened new Acadia Pharmaceuticals positions in Q1 2016 and 39 closed out, a net change of -1 holder.
- The largest Acadia Pharmaceuticals buyer in Q1 2016 was Baker Bros. Advisors, an estimated $81.4M added.
- The largest Acadia Pharmaceuticals seller in Q1 2016 was Westfield Capital Management, an estimated $32M sold.
Based on aggregated 13F filings for Q1 2016.